Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Indian (NIFTY) Pharma Industry Analysis

UpdatedApr 01, 2026
DataAggregated Company Financials
Companies181
  • 7D-0.3%
  • 3M-2.9%
  • 1Y1.4%
  • YTDn/a

Last week, the Pharma industry hasn't moved much but Ipca Laboratories is up 4.6% in that time. In line with that, the industry has also been flat over the past 12 months. As for the next few years, earnings are expected to grow by 16% per annum.

Industry Valuation and Performance

Has the Indian Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Thu, 02 Apr 2026₹19.8t₹4.3t₹621.3b24.5x31.9x4.6x
Sat, 28 Feb 2026₹20.5t₹4.3t₹621.1b26.2x32.9x4.7x
Mon, 26 Jan 2026₹19.5t₹4.2t₹605.2b29.1x32.2x4.6x
Wed, 24 Dec 2025₹20.6t₹4.2t₹614.5b29.4x33.5x4.9x
Fri, 21 Nov 2025₹20.4t₹4.2t₹611.2b29.5x33.4x4.9x
Sun, 19 Oct 2025₹20.3t₹4.1t₹589.9b30.6x34.4x5x
Tue, 16 Sep 2025₹20.5t₹4.1t₹589.1b31.7x34.8x5x
Thu, 14 Aug 2025₹20.2t₹4.1t₹588.7b30.6x34.4x5x
Sat, 12 Jul 2025₹20.4t₹4.0t₹594.1b32.6x34.3x5.1x
Mon, 09 Jun 2025₹20.2t₹4.0t₹595.3b32x33.9x5.1x
Wed, 07 May 2025₹19.4t₹3.9t₹563.0b28.9x34.4x5x
Fri, 04 Apr 2025₹19.6t₹3.9t₹559.4b29.6x35.1x5x
Sun, 02 Mar 2025₹18.0t₹3.9t₹559.4b26.2x32.3x4.6x
Tue, 28 Jan 2025₹19.4t₹3.8t₹531.6b30.4x36.5x5.1x
Thu, 26 Dec 2024₹20.8t₹3.8t₹526.7b34.8x39.4x5.5x
Sat, 23 Nov 2024₹20.3t₹3.8t₹526.7b31.7x38.5x5.3x
Mon, 21 Oct 2024₹21.4t₹3.7t₹492.6b40.1x43.4x5.7x
Wed, 18 Sep 2024₹21.6t₹3.7t₹492.6b41.8x44x5.8x
Fri, 16 Aug 2024₹20.2t₹3.8t₹492.2b35.6x41.1x5.4x
Sun, 14 Jul 2024₹18.6t₹3.6t₹449.9b35x41.4x5.2x
Tue, 11 Jun 2024₹17.4t₹3.6t₹448.1b33x38.8x4.9x
Thu, 09 May 2024₹16.9t₹3.5t₹423.6b33.8x39.8x4.8x
Sat, 06 Apr 2024₹17.2t₹3.5t₹418.9b33.6x41.1x4.9x
Mon, 04 Mar 2024₹17.0t₹3.5t₹418.7b33.7x40.6x4.9x
Wed, 31 Jan 2024₹15.8t₹3.4t₹396.1b34.6x39.9x4.7x
Fri, 29 Dec 2023₹14.9t₹3.4t₹395.2b32.5x37.7x4.4x
Sun, 26 Nov 2023₹14.0t₹3.4t₹395.1b31x35.6x4.2x
Tue, 24 Oct 2023₹12.8t₹3.3t₹368.0b29.1x34.9x3.9x
Thu, 21 Sep 2023₹13.2t₹3.3t₹369.5b29.9x35.7x4x
Sat, 19 Aug 2023₹13.0t₹3.3t₹367.1b29.1x35.5x4x
Mon, 17 Jul 2023₹11.9t₹3.2t₹342.6b26.3x34.8x3.8x
Wed, 14 Jun 2023₹11.1t₹3.2t₹342.4b25.9x32.5x3.5x
Fri, 12 May 2023₹10.5t₹3.1t₹306.0b27.2x34.4x3.4x
Sun, 09 Apr 2023₹9.8t₹3.0t₹277.5b24.5x35.2x3.3x
Price to Earnings Ratio

35.2x


Total Market Cap: ₹9.8tTotal Earnings: ₹277.5bTotal Revenue: ₹3.0tTotal Market Cap vs Earnings and Revenue0%0%0%
Indian Pharma Industry Price to Earnings3Y Average 36.5x202420252026
Current Industry PE
  • Investors are pessimistic on the Indian Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 31.9x which is lower than its 3-year average PE of 36.5x.
  • The industry is trading close to its 3-year average PS ratio of 4.7x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have grown 31% per year over the last three years.
  • Revenues for these companies have grown 13% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Comparison

How does Indian Pharma compare with similar industries?

IN Market-2.63%
Healthcare-0.54%
Pharma-0.28%
Pharma-0.28%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
AUROPHARMA Aurobindo Pharma₹1.34k2.6%
+₹19.9b		15.9%PE22.4x
WOCKPHARMA Wockhardt₹1.27k5.9%
+₹11.4b		-11.9%PE936.3x
LAURUSLABS Laurus Labs₹1.04k1.5%
+₹8.3b		70.6%PE66.5x
SANOFICONR Sanofi Consumer Healthcare India₹4.54k7.5%
+₹7.3b		-5.5%PE43.5x
524558 Neuland Laboratories₹12.60k4.4%
+₹6.8b		8.9%PE90.3x

Latest News

500124
₹1,209.20
Dr. Reddy's Laboratories
7D
-7.1%
1Y
5.2%
500257
₹2,273.60
Lupin
7D
-3.1%
1Y
13.1%
530549
₹374.20
Shilpa Medicare
7D
8.3%
1Y
15.5%
ZYDUSLIFE
₹863.20
Zydus Lifesciences
7D
-4.5%
1Y
-3.1%

ZYDUSLIFE: Diabetes And Obesity Portfolio And US Approvals Will Shape A Balanced Outlook

Analysts have trimmed their price target on Zydus Lifesciences slightly from ₹993.73 to ₹992.07, reflecting updated assumptions around revenue, profit margins and future P/E expectations. What's in the News Zydus launched Semaglutide injection in India under the brands SEMAGLYN, MASHEMA and ALTERME, using a reusable multi dose pen device for Type 2 diabetes and obesity, with an estimated treatment cost of about ₹2,200 per month.
SUNPHARMA
₹1,728.50
Sun Pharmaceutical Industries
7D
-3.7%
1Y
0.9%

SUNPHARMA: Obesity And Diabetes Launches And Disciplined Mergers Will Guide Balanced Outlook

Analysts have trimmed their price target for Sun Pharmaceutical Industries slightly to around ₹1,961 from about ₹1,976, reflecting updated assumptions that keep revenue growth, profit margin and future P/E expectations broadly similar to prior estimates. What's in the News Launch of semaglutide injections Noveltreat and Sematrinity in India for chronic weight management and type 2 diabetes, with weekly therapy costs reported in the INR 750 to INR 2,000 range to support affordability across multiple dose strengths (Key Developments).
CIPLA
₹1,195.90
Cipla
7D
-3.9%
1Y
-17.7%

CIPLA: New CEO And Biologics Venture Will Support Stronger Long Term Outlook

Analysts have trimmed Cipla's implied fair value price target slightly from ₹1,446.31 to ₹1,436.58, reflecting updated views on its revenue growth, profit margin outlook, and future P/E assumptions. What's in the News A board meeting is scheduled for 19 Mar 2026 to consider appointing P R Ramesh, Lead Independent Director, as Vice Chairman, and to take up the planned exit of Independent Director Robert Stewart after completion of his current term, along with other matters (Key Developments).
AUROPHARMA
₹1,342.10
Aurobindo Pharma
7D
2.6%
1Y
15.9%

AUROPHARMA: Lower P/E Expectations Will Challenge Execution On Margin Assumptions

Narrative Update on Aurobindo Pharma The analyst price target for Aurobindo Pharma has been adjusted slightly lower from about ₹1,046.76 to about ₹1,033.98 as analysts factor in updated assumptions for revenue growth, profit margins and future P/E expectations. Analyst Commentary Recent Street research on other companies shows a mix of optimism and caution, and the modest reduction in the average price target for Aurobindo Pharma to about ₹1,033.98 fits into that more measured tone.
ALKEM
₹5,244.50
Alkem Laboratories
7D
-3.5%
1Y
7.3%

ALKEM: Long Dated US Settlements Will Support ReRating

Analysts have kept Alkem Laboratories' fair value estimate steady at ₹6,913, reflecting only minor model tweaks to revenue growth, profit margin, and future P/E assumptions rather than a material shift in their overall view. What's in the News Received a Certificate of GMP Compliance from the German health authority for the Baddi, India manufacturing facility, valid for three years from the November 4 to 10, 2025 inspection.
500420
₹4,108.55
Torrent Pharmaceuticals
7D
-4.4%
1Y
28.0%

500420: Patent Dispute And Planned Dividends Will Shape Future Risk Balance

The analyst price target for Torrent Pharmaceuticals has shifted slightly higher to ₹4,498.68 from ₹4,487.96, with analysts pointing to stable assumptions around discount rate, revenue growth, profit margins, and a marginally higher future P/E multiple as the key drivers behind this refinement. What's in the News Xeris Biopharma Holdings and its subsidiaries filed a Hatch-Waxman patent infringement lawsuit in the U.S. District Court for the District of New Jersey against Torrent Pharmaceuticals and Somerset Therapeutics related to generic versions of Recorlev (levoketoconazole).
NATCOPHARM
₹1,001.90
NATCO Pharma
7D
2.9%
1Y
24.2%

NATCOPHARM: Diabetes Franchise Partnership And Demerger Plan Will Support Future Upside

Analysts have nudged their fair value estimate for NATCO Pharma slightly higher from ₹1,378.76 to ₹1,391.29, citing small adjustments to expected revenue contraction, profit margins and future P/E assumptions. What's in the News The board is scheduled to meet on March 24, 2026 to consider a Scheme of Arrangement to demerge the Agrochemicals Division into wholly owned subsidiary Natco Crop Health Sciences Limited, on a going concern basis (Board Meeting).
524558
₹12,604.90
Neuland Laboratories
7D
4.4%
1Y
8.9%

524558: Phase 2 Peptide Progress And 2026 Board Meeting Will Support Upside Potential

Analysts have kept their fair value estimate for Neuland Laboratories steady at ₹18,865.25. This reflects unchanged assumptions around the discount rate, revenue growth, profit margin and future P/E expectations.
LAURUSLABS
₹1,038.80
Laurus Labs
7D
1.5%
1Y
70.6%

LAURUSLABS: Higher Margin Assumptions Will Likely Struggle Against Execution Risks

Narrative Update on Laurus Labs The updated analyst price target for Laurus Labs moves from about ₹330 to roughly ₹540. Analysts point to revised assumptions for margins and future P/E, along with broadly steady growth expectations, as key drivers of the change.
GLENMARK
₹2,101.10
Glenmark Pharmaceuticals
7D
-3.1%
1Y
38.6%

GLENMARK: Upcoming US Respiratory Launch Will Support Future Upside

Analysts have kept Glenmark Pharmaceuticals' fair value estimate steady at ₹2,735, reflecting slightly updated assumptions on revenue growth, profit margin, and future P/E that currently offset each other in their price target models. What's in the News Glenmark Specialty SA received final U.S. FDA approval for Fluticasone Propionate Inhalation Aerosol USP, 44 mcg per actuation, which is rated bioequivalent and therapeutically equivalent to FloVent HFA 44 mcg of GlaxoSmithKline (Product-Related Announcements).
SANOFICONR
₹4,535.70
Sanofi Consumer Healthcare India
7D
7.5%
1Y
-5.5%
PFIZER
₹4,853.00
Pfizer
7D
3.0%
1Y
19.9%
WOCKPHARMA
₹1,267.60
Wockhardt
7D
5.9%
1Y
-11.9%